OREANDA-NEWS. Deltex Medical Group plc (LSE-AIM: DEMG), the global leader in oesophageal Doppler monitoring ("ODM"), announces that it has added a further new account to its platform programme in the USA.

The account is a major hospital in the Mid-West and is the first platform programme account in the Great Lakes sales territory which the Company established in the first quarter of 2015.

The hospital has committed to purchase at least 65 probes per month during its initial implementation phase.

Ewan Phillips, Deltex Medical's Chief Executive, commented:

"The US is an increasingly important market for us and we are pleased to have this, the sixth account added to our US platform programme this year and the twelfth in total. Deltex Medical is making good progress towards our current goal of 30 US hospitals on its platform programme by mid-2016."